Invivyd (NASDAQ:IVVD) said its first quarter of 2026 was marked by continued progress in its pivotal COVID-19 antibody program, year-over-year growth for PEMGARDA and elevated clinical spending tied to its VYD2311 development efforts.
On the company’s earnings call, Chairman Marc Elia said Invivyd’s pivotal DECLARATION study for VYD2311 remains on schedule after the company triggered an upsizing of the study in early April. Elia said recruitment into the expanded cohort moved “well faster” than internal expectations, prompting Invivyd to slow enrollment temporarily during a lull in COVID-19 and broader respiratory disease activity in order to extend patient exposure into what the company expects could be a normal summer COVID wave.
